Mostrando 4 resultados de: 4
Filtros aplicados
Publisher
American Journal of Obstetrics and Gynecology(1)
Gynecological Endocrinology(1)
Maturitas(1)
Revista Espanola de Enfermedades Metabolicas Oseas(1)
Origen
scopus(4)
EMAS position statement: The ten point guide to the integral management of menopausal health
ArticleAbstract: With increased longevity and more women becoming centenarians, management of the menopause and postrPalabras claves:Hot Flushes, menopausal hormone therapy, MENOPAUSE, OSTEOPOROSIS, Postreproductive health, screeningAutores:Birkhauser M., Ceausu I., Depypere H., Erel T., Faustino R. Pérez-López, Lambrinoudaki I., Llaneza P., Neves-E-Castro M., Palacios S., Rees M., Samsioe G., Sánchez-Borrego R., Schenck-Gustafsson K., Simoncini T., Trémollieres F.A., van der Schouw Y.T.Fuentes:scopusEfficacy and safety of the aminobisphosphonate in the treatment of postmenopausal osteoporosis
ReviewAbstract: Aminobisphosphonates are a drug family widely used in the treatment of postmenopausal osteoporosis,Palabras claves:Alendronate, Aminobisphosphonates, Bisphosphonates, Efficacy, Frozen bone, OSTEOPOROSIS, safetyAutores:Faustino R. Pérez-López, Ferrer Barriendos J., Gómez De La Cámara A., Palacios S., Quereda Seguí F., Quesada Gómez M., Rodríguez Arboleya L., Vázquez Fernández F.Fuentes:scopusVitamin D supplementation: position Statement of the Iberoamerican Society of Osteoporosis and Mineral Metabolism (SIBOMM)
ArticleAbstract: Background: Vitamin D (VD) deficiency is a global pandemic that affects more than a third of the popPalabras claves:Latin America, recommendations, supplementation, vitamin DAutores:Cerdas S., Córdoba S., Da Silva R., de Melo N.R., Luis Fernando Danckers, Maida T., Melo L., Moreno M., Mostajo D., Muñoz-Louis R., Navas M., Palacios S., Paradas A., Rasec-Morales L., Rosero O., Rueda C., Tserotas K., Vargas J., Vasquez D.Fuentes:scopusRaloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate
ArticleAbstract: Objectives Raloxifene is approved for the treatment and prevention of postmenopausal osteoporosis. PPalabras claves:Hot Flushes, OSTEOPOROSIS, Postmenopausal women, Raloxifene, Selective estrogen receptor modulatorsAutores:Almeida M.J., Gustavo J. Gómez, Kayath M.J., Lucia F. Farias M., Luebbert H., Mönnig E., Nickelsen T., Palacios S., Quail D.C., Turbi C., Yabur J.A.Fuentes:scopus